<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-133 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-133</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-133</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-6.html">extraction-schema-6</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <p><strong>Paper ID:</strong> paper-781c2a94a79681aefbd2424cc597edb31a6f428d</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/781c2a94a79681aefbd2424cc597edb31a6f428d" target="_blank">Non-small cell lung cancer: current treatment and future advances.</a></p>
                <p><strong>Paper Venue:</strong> Translational Lung Cancer Research</p>
                <p><strong>Paper TL;DR:</strong> Current treatments including surgery, chemotherapy, radiotherapy, and immunotherapy are discussed as well as how biomarker testing has helped improve survival in patients with NSCLC.</p>
                <p><strong>Cost:</strong> 0.022</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e133.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e133.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Smoking intensity/duration</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cigarette smoking intensity and duration (packs per day, years smoked)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Degree and duration of cigarette smoking (years smoked and packs per day) increase lung cancer risk in a dose-dependent manner; smoking is the leading risk factor and attributed to the majority of lung cancer deaths.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The Health Consequences of Smoking-50 Years of Progress. A Report of the Surgeon General, 2014.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>review / epidemiologic evidence (summarized observational studies)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Summary across many cohort and case-control studies of cigarette smokers and nonsmokers; demographic details vary by study and are not specified in aggregate in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Greater number of years smoked and greater packs/day increase lung cancer risk; cigarette smoking is stated as the leading risk factor and causes at least 80% of lung cancer deaths.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Not directly quantified in the paper; implied protective actions include lower cumulative exposure (fewer years/packs) and cessation (by implication from dose-response), but no direct effect estimates provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>No specific genetic modifiers provided in this section, though later sections describe genetic susceptibility that interacts with smoking.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Intensity (packs/day) and duration (years) of smoking; introduction of filters changed particle size and may have altered inhalation patterns (see inhalation depth/filter entry).</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Co-exposures (radon, occupational carcinogens, air pollution) modify absolute risk when combined with smoking (described elsewhere in review).</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Tobacco smoke contains carcinogens that damage DNA leading to mutations and tumorigenesis (general mechanism referenced).</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>Smoking accounts for at least ~80% of lung cancer deaths (stated).</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Not all smokers develop lung cancer despite high exposure; review emphasizes other modifying genetic and environmental factors that help explain variability.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Statement is based on aggregate epidemiologic evidence summarized in reviews; individual study heterogeneity and confounding (e.g., co-exposures) are not detailed here.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e133.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e133.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Passive smoking</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Environmental tobacco smoke exposure (passive smoking)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Living with a smoker or long-term exposure to secondhand smoke increases lung cancer risk for never-smokers; evidence from meta-analyses and comprehensive reviews shows elevated relative risks.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Environmental exposure to carcinogens causing lung cancer: epidemiological evidence from the medical literature.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>meta-analysis and comprehensive review (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Never-smokers exposed to household smokers, across multiple studies and populations (not aggregated to a single sample size in this review).</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Household exposure to a smoker increases lung cancer risk among never-smokers; living with a smoker increases a nonsmoker's chance of developing lung cancer by ~20–30%.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Reducing or eliminating household exposure to smokers reduces the risk (implied), no quantitative protective estimate provided.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>Not addressed specifically in the passive-smoking section.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Co-habitation with a smoker and duration of exposure to household smoke.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Passive smoke is an environmental exposure that acts additively with other exposures like radon or occupational carcinogens.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Secondhand smoke contains carcinogens similar to mainstream smoke, leading to DNA damage and increased cancer risk.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>Meta-analysis reported relative risks in the range 1.14–5.20 for never-smokers who lived with a smoker; Surgeon General summary cites ~20–30% increased risk for living with a smoker.</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Range of RR (1.14–5.20) indicates heterogeneity across studies and populations; not all exposed never-smokers develop lung cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Heterogeneity across studies, potential exposure misclassification and confounding in primary studies; summary range wide, reflecting variable methodologies.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e133.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e133.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Radon</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Residential radon exposure</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Radon gas exposure in homes is a recognized lung carcinogen linked to increased lung cancer incidence and is estimated to account for thousands of lung cancer deaths in the U.S.; evidence comes from pooled case-control and collaborative analyses.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>combined analyses / pooled case-control studies (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Multiple case-control studies across North America, Europe and China (references include pooled analyses of 7 North American studies and 13 European case-control studies); specifics not aggregated in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Residential radon exposure at levels around 2.7 pCi/L associated with increased lung cancer incidence; approximately 21,000 U.S. lung cancer deaths linked to radon exposure (stated estimate).</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Lower residential radon levels (remediation) would reduce risk (implied), no specific protective estimates provided.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>Genetic susceptibility to radon-induced cancer not described in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Occupancy patterns (time spent in basements or home) would modify exposure but are not quantified here.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Radon acts alongside smoking to increase absolute risk; historically linked with mine workers and now indoor residential exposure is a concern.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Radon delivers alpha-particle radiation to bronchial epithelium causing DNA damage and carcinogenesis.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>Residential radon exposure at ~2.7 pCi/L associated with increased lung cancer risk in pooled studies; estimated ~21,000 U.S. lung cancer deaths attributable to radon (stated).</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Not all radon-exposed individuals develop lung cancer; interaction with smoking increases risk substantially.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Heterogeneity between studies, exposure measurement uncertainty, and potential confounding by smoking in some analyses.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e133.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e133.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Occupational exposures</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Occupational carcinogen exposures (asbestos, arsenic, beryllium, cadmium, silica, nickel, chromium, diesel exhaust, etc.)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Various occupational exposures are linked to elevated lung cancer risk; asbestos in particular has a well-established causal relationship and fiber size influences mortality risk.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>epidemiologic studies and occupational cohort/case-control analyses (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Workers with documented occupational exposures in industrial and mining settings (studies vary by agent and cohort); aggregated details not provided in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Occupational exposure to asbestos, arsenic compounds, beryllium, cadmium, silica, vinyl chloride, nickel and chromium compounds, coal products, mustard gas, chloromethyl esters, and diesel exhaust are associated with increased lung cancer risk.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Regulatory reduction or cessation of exposures (e.g., reduced asbestos use) are implied protective measures; no quantitative protective estimates provided.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>No specific genetic modifiers of occupational risk described in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Workplace safety behaviors and use of protective equipment would modify risk but are not quantified here.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Occupational exposures can act synergistically with smoking to increase lung cancer risk.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Carcinogenic agents induce DNA damage, chronic inflammation, and other carcinogenic processes in lung tissue; asbestos fiber size linked to mortality differences.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>No single summary RR provided in review; specific studies cited document increased risks varying by agent and exposure characteristics.</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Some exposed workers may not develop lung cancer, reflecting dose, fiber type, co-exposures, and genetic susceptibility differences.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Heterogeneity of exposures, difficulty in accurate retrospective exposure assessment, and potential confounding by smoking in occupational cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e133.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e133.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Air pollution (PM/fine particulates)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Long-term exposure to fine particulate air pollution and traffic-related pollutants (polycyclic aromatic hydrocarbons)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Chronic exposure to air pollution, particularly fine particulate matter and polycyclic aromatic hydrocarbons from traffic, is associated with increased lung cancer mortality and incidence.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>cohort studies / epidemiologic analyses (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Urban and peri-urban populations with long-term exposure to traffic-related air pollution; specifics derived from large cohort analyses (e.g., the cited JAMA study).</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Long-term exposure to fine particulate air pollution linked to increased lung cancer mortality; cited association is an 8% increased risk of all-cause lung cancer mortality.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Reduced exposure to ambient PM and traffic emissions expected to lower risk (implied), not quantified here.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>Not described in this section.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Residential location and time spent outdoors/near traffic modify exposure; not quantified.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Air pollution is an independent environmental risk factor and may add to smoking-related risk.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Particulate matter and associated chemicals (e.g., PAHs) induce genotoxic and inflammatory effects in the lung contributing to carcinogenesis.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>Air pollution associated with an ~8% increased risk of all-cause lung cancer mortality (cited meta/cohort result).</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Heterogeneity across regions and varying pollution mixtures mean not all exposed populations show equal increases.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Exposure measurement error, confounding by smoking, and variability in pollutant mixtures across studies.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e133.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e133.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>TP53 germline</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Germline TP53 sequence variations (p53 mutation carriers)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Individuals carrying germline TP53 mutations who also smoke have substantially increased lung cancer risk compared to nonsmokers, indicating gene–environment interaction.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>observational / genetic epidemiology study (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Individuals with germline TP53 sequence variations (mutation carriers); details on sample size not provided in the review summary.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Smoking among TP53 germline mutation carriers increases lung cancer risk to more than 3 times that of nonsmokers (as reported).</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Absence of a germline TP53 mutation would reduce this particular inherited susceptibility; no specific protective factors quantified.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>Germline TP53 mutations confer inherited predisposition; interaction with smoking amplifies risk (>3x reported estimate).</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Smoking behavior modifies penetrance of TP53-associated risk (smokers >3x risk compared to nonsmokers among carriers).</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Additional exposures (not specified) could further modify risk in carriers.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>TP53 is a tumor suppressor; germline loss or mutation impairs DNA damage response and apoptosis, increasing susceptibility to carcinogen-induced transformation from tobacco smoke.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>Carriers of germline TP53 variants who also smoke are reported to be >3 times more likely to develop lung cancer than nonsmokers (specific CI or p-value not provided in review).</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Not all TP53 mutation carriers necessarily develop lung cancer; penetrance varies with exposures and other modifiers.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Sample sizes and details not provided in the review; primary study likely limited by rarity of germline TP53 carriers and potential ascertainment bias.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e133.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e133.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Chr15 nicotinic locus</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Chromosome 15q25 locus (nicotinic acetylcholine receptor subunit genes)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A genetic susceptibility locus on chromosome 15 containing genes for nicotinic acetylcholine receptor subunits has been associated with nicotine dependence and increased lung cancer risk in GWAS; risk increases with allele dose.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>A variant associated with nicotine dependence, lung cancer and peripheral arterial disease.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>genome-wide association studies (cited, multiple independent GWAS)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Multiple independent genetic studies (GWAS) across populations; specific sample sizes are in the cited GWAS papers but not aggregated in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Carriers of the risk marker on 15q25 have increased lung cancer risk: one copy associated with ~30% increased risk; two copies associated with ~70–80% increased risk (as reported from three independent studies). This locus also relates to nicotine dependence.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Non-carriers of the risk allele(s) at 15q25 would have lower genetic susceptibility (implied).</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>The marker contains three genes for subunits of the nicotinic acetylcholine receptor; association suggests genetic influence on nicotine dependence and potential direct effects on carcinogenesis.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Alleles at this locus influence nicotine dependence, which may alter smoking intensity/behavior and thereby mediate lung cancer risk.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Variant effects interact with smoking exposure (influencing both behavior and biological responses to nicotine/carcinogens).</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Variants might affect receptor-mediated responses to nicotine (nicotine 'latching' to receptor proteins) and influence smoking behavior and possibly direct carcinogenic pathways via receptor signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>One copy of the marker: ~30% increased risk; two copies: ~70–80% increased risk (reported across three independent studies).</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Not all carriers develop lung cancer; gene effect sizes are moderate and interact with behavior and exposure.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>GWAS associations may reflect linkage disequilibrium with causal variants; confounding by smoking behavior complicates causal interpretation (smoking behavior mediation vs direct effect).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e133.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e133.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR mutations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal growth factor receptor (EGFR) activating somatic mutations</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Somatic activating EGFR mutations (commonly exon 19 deletions and L858R on exon 21) occur in a subset of lung adenocarcinomas and are enriched in never-smokers, females, and certain ethnicities, with implications for tumor biology and treatment sensitivity.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>molecular epidemiology / tumor genomics studies (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>EGFR mutations present in ~10–15% of lung adenocarcinomas in patients of European and Asian descent; more common in never-smokers and females (summary across cited studies).</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>EGFR-mutant tumors are more common in never-smokers; thus the presence of EGFR mutations distinguishes a subset of lung cancer not strongly linked to heavy smoking.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Not applicable as EGFR mutations are oncogenic; however, tumors with these mutations respond well to EGFR-targeted therapy (treatment sensitivity, not prevention).</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>About 90% of clinically relevant EGFR mutations are exon 19 deletions and exon 21 L858R point mutations; these confer sensitivity to EGFR tyrosine kinase inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>EGFR mutations are more frequent in never-smokers, indicating smoking status is inversely associated with this molecular subtype.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Not explicitly linked to environmental co-exposures in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Mutations produce constitutive activation of EGFR tyrosine kinase leading to uncontrolled proliferation; underpin mechanism for targeted therapy response.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>EGFR mutations present in ~10–15% of lung adenocarcinomas in the populations cited; exon 19 deletions and L858R comprise ~90% of mutations and are correlated with ~70% response rates to EGFR inhibitors (erlotinib/gefitinib) in mutation-positive patients.</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>EGFR-driven cancers occur preferentially in never-smokers, so smokers developing lung cancer often have other driver mutations (e.g., KRAS); presence of EGFR mutation does not explain why some smokers (who lack EGFR mutations) do or do not develop cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Mutation prevalence varies by ethnicity and smoking history; studies are tumor-based and describe patients with cancer rather than risk in a smoking cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e133.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e133.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRAS mutations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KRAS oncogenic somatic mutations (eg. G12, G13, G12C)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>KRAS mutations are a common oncogenic driver in NSCLC, especially adenocarcinoma in smokers and Caucasians; certain KRAS subtypes (e.g., G12C) are being targeted by emerging inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>KRAS mutations in non-small cell lung cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>molecular epidemiology / tumor genomics studies (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>KRAS mutations identified in approximately 10–25% of lung adenocarcinomas; more frequent in Caucasians and individuals with a smoking history (summary across cited studies).</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>KRAS mutations are more frequently found in tumors from smokers, indicating a smoking-associated molecular pathway for tumorigenesis.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Not described; presence of KRAS is associated with lack of overlap with EGFR/ALK driver mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>Missense mutations substituting amino acids at codons 12, 13 or 61 (notably G12 and G13) predominate; subtype G12C is common in smokers and a target for specific inhibitors.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Smoking history correlates with higher KRAS mutation frequency in tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Not explicitly detailed beyond smoking association.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>KRAS mutations activate downstream proliferative signaling pathways, providing a mechanistic link between carcinogen-induced DNA damage and transformed phenotypes.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>KRAS mutations occur in ~10–25% of adenocarcinoma cases (reported); specific prevalence varies by study and population.</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>KRAS mutations tend not to overlap with EGFR or ALK mutations (non-overlapping molecular subsets).</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Tumor-based prevalence data do not directly address relative risk among smokers vs non-smokers in the population; causal inference from tumor associations is limited.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e133.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e133.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ALK rearrangements</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Anaplastic lymphoma kinase (ALK) gene rearrangements (e.g., EML4-ALK)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>EML4-ALK and other ALK fusions define a distinct molecular subset of NSCLC, enriched in younger patients and in never- or light-smokers; these rearrangements are targetable therapeutically but are uncommon overall.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>molecular characterization studies and clinical trials (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>ALK rearrangements occur in ~3–7% of lung tumors; Koh et al. reported median age 49 in ALK-positive patients vs 61 in ALK-negative (P<0.001; n=221 in that study). ALK-positive tumors are more common in adenocarcinomas and in never/light smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>ALK rearrangements are associated with specific clinical features (younger age, adenocarcinoma histology, nonsmoking or light smoking history) rather than being caused by smoking.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Not a protective factor; rather, its enrichment in never-smokers indicates alternate non-tobacco etiologies for some lung cancers.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>Multiple fusion partners (EML4-ALK most common) with at least nine fusion variants; EML4-ALK rearrangements occur on chromosome 2p23.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>More common in never-smokers/light smokers, implying smoking status influences the distribution of molecular subtypes.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Not linked to specific environmental exposures in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>ALK fusions create constitutively active tyrosine kinase signaling driving tumor growth; tumors with ALK fusions respond to ALK inhibitors like crizotinib.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>ALK rearrangements in ~3–7% of lung tumors; crizotinib demonstrated PFS 10.9 vs 7 months and ORR 74% vs 45% compared with platinum-pemetrexed chemotherapy in ALK-positive patients (treatment trial results cited).</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>ALK-positive tumors are generally non-overlapping with other oncogenic driver mutations like EGFR or KRAS.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>ALK prevalence is low; findings derive from tumor cohorts and clinical trials with selection of ALK-positive patients, limiting generalizability to population-level susceptibility.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e133.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e133.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Filter cigarettes / inhalation depth</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cigarette design (filters) and inhalation depth leading to peripheral adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Introduction of filters in cigarettes is hypothesized to alter particle deposition and promote deeper inhalation of smoke, potentially shifting tumor location toward peripheral lungs and increasing adenocarcinoma incidence.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Impact of filter cigarette smoking on lung cancer histology.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>observational/histologic comparisons (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Histologic analyses comparing tumor site and histology in relation to smoking behaviors and cigarette types; exact sample sizes vary by cited studies and are not aggregated here.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Use of filter cigarettes may lead to deeper inhalation of smoke and increased peripheral lesions (adenocarcinoma); this behavioral/technological change modifies the pattern of lung cancer histology among smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Not presented as protective; filters may reduce some large particle deposition but may unintentionally increase peripheral small-particle deposition.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>No genetic findings linked directly to filter use presented.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Depth of inhalation is a behavioral modifier influenced by cigarette design (filters) and smoking technique.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Design changes alter exposure distribution within the lung (an exposure distribution modifier rather than an external environmental modifier).</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Smaller particles penetrate deeper into the peripheral lung causing carcinogenic insult to alveolar/type II cells, contributing to more peripheral adenocarcinomas.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>Review notes association of filter cigarettes with peripheral lesions but does not provide quantitative RR estimates in this summary.</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Not all filter cigarette smokers develop peripheral adenocarcinomas; many factors (genetics, total exposure) influence outcomes.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Hypothesis based on epidemiologic trends and particle deposition theory; causal linkage is complex and confounded by simultaneous changes in tobacco composition and smoking behavior.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e133.11">
                <h3 class="extraction-instance">Extracted Data Instance 11 (e133.11)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Immune factors / TGF-β2</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Immune microenvironment factors and immunosuppressive mediators (e.g., TGF-β2, tumor-infiltrating lymphocytes)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Differences in antitumor immune response and immunosuppressive signals can influence prognosis and may contribute to why some smokers develop clinically significant lung cancer while others do not; higher intratumoral CD4+, CD8+, NK and dendritic cells associate with better survival, while elevated TGF-β2 can suppress immune function.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>observational tumor immunology studies and vaccine trial correlative findings (cited)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Patients with NSCLC whose tumors were analyzed for immune infiltrates and cytokine levels; specific cohorts and sizes are study-specific and not aggregated here.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Immunosuppressive tumor environment (e.g., higher TGF-β2) and lower numbers of tumor-infiltrating effector immune cells correlate with poorer outcomes, implying weaker anti-tumor immunity may permit progression.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Higher numbers of CD4+, CD8+, natural killer cells, dendritic cells and presence of intratumoral lymphoid structures are associated with improved survival (protective for prognosis).</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>Not emphasized here; immune phenotypes are presented as prognostic/biologic modifiers rather than inherited genetic variants.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Not directly behavioral; prior treatments (radiation, chemotherapy) and vaccination strategies can modulate immune status (discussed in vaccine sections).</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Not directly environmental; systemic exposures that alter immune function could modify risk but are not detailed.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>TGF-β2 suppresses NK cell function and dendritic cell activity; immune checkpoint pathways (CTLA-4, PD-1/PD-L1) regulate T cell activity and tumor immune escape; effective antitumor immune responses limit tumor progression.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>Vaccine and immune-correlation studies reported relationships between antibody/t-cell responses and survival (e.g., good anti-EGF antibody responders had median OS 11.7 vs 3.6 months for poor responders in one CIMAVax trial), and higher effector cell counts associated with better outcomes in cited immunology studies.</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Some patients with robust immune infiltrates still progress, and some with low infiltrates have indolent disease; immune contexture is one of multiple interacting determinants.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Correlative nature of immune studies limits causal inference; immune biomarkers vary by assay and tumor sampling; many observations derive from post-diagnosis tumor analyses rather than prospective risk stratification in smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Non-small cell lung cancer: current treatment and future advances.', 'publication_date_yy_mm': '2016-06'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>A variant associated with nicotine dependence, lung cancer and peripheral arterial disease <em>(Rating: 2)</em></li>
                <li>A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. <em>(Rating: 2)</em></li>
                <li>Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1 <em>(Rating: 2)</em></li>
                <li>Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. <em>(Rating: 2)</em></li>
                <li>Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. <em>(Rating: 2)</em></li>
                <li>Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. <em>(Rating: 2)</em></li>
                <li>Tobacco smoke carcinogens and lung cancer. <em>(Rating: 2)</em></li>
                <li>Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution. <em>(Rating: 2)</em></li>
                <li>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. <em>(Rating: 2)</em></li>
                <li>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>